New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 280-286

  Jorgensen, James H ^a   Hindler, Janet F ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; GENTAMICIN; GLYCOPEPTIDASE; LINCOSAMIDE DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ABIOTROPHIA; ACTINOBACILLUS; AEROMONAS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACILLUS; BACILLUS ANTHRACIS; BACILLUS THURINGIENSIS; BACTERIAL ENDOCARDITIS; BACTERIUM ISOLATE; CAMPYLOBACTER COLI; CAMPYLOBACTER JEJUNI; CARDIOBACTERIUM; DEVICE INFECTION; EIKENELLA; ENVIRONMENTAL EXPOSURE; ERYSIPELOTHRIX; GRAM NEGATIVE BACTERIUM; GRANULICATELLA; HAEMOPHILUS; KINGELLA; LABORATORY; LACTOBACILLUS; LEUCONOSTOC; LISTERIA; MORAXELLA CATARRHALIS; NONHUMAN; PASTEURELLA; PEDIOCOCCUS; PRIORITY JOURNAL; REVIEW; STANDARD; VIBRIO;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; LABORATORIES; MICROBIAL SENSITIVITY TESTS;

EID: 33846143176     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510431     Document Type: Review

References (50)

1. Klastersky J, Aoun M. Opportunistic infections in patients with cancer. [Review] Ann Oncol 2004; 15(Suppl 4):329-35.
2. Arciola CR, An YH, Campoccia D, et al. Etiology of implant orthopedic infections: a survey on 1027 clinical isolates. Int J Artif Organs 2005; 28: 1091-100.
3. Campoccia D, Montanaro L, Arciola CR. The significance of infection related to orthopedic devices and issues of antibiotic resistance review]. Biomaterials 2006; 27:2331-9.
4. Christensen JJ, Facklam RR. Granulicatella and Abiotrophia species from human clinical specimens. J Clin Microbiol 2001; 39:3520-3.
5. Das M, Badley AD, Cockerill FR, et al. Infective endocarditis caused by HACEK microorganisms. Ann Rev Med 1997; 48:25-33.
6. Jones BL, Wilcox MH. Aeromonas infections and their treatment. J Antimicrob Chemother 1995; 35:453-61.
7. Chiang SR, Chuang YC. Vibrio vulnificus infection: clinical manifestations, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 2003; 36:81-8.
8. Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. N Engl J Med 1999; 340:85-92.
9. Gorby GL, Peacock JE. Erysipelothrix rhusiopathiae endocarditis: microbiologic, epidemiologic, and clinical features of an occupational disease. Rev Infect Dis 1988; 10:317-25.
10. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A7. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
11. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A9. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
12. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplement M100-S16. Clinical and Laboratory Standards Institute: Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
13. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A6. Wayne, PA: NCCLS, 2004.
14. NCCLS. Development of in vitro susceptibility testing criteria and quality control parameters. NCCLS document M23-A2. Wayne, PA: NCCLS, 2001.
15. Craig WA. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
16. Montgomery MJ, Beringer PM, Aminimanizani A, et al. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:3468-73.
17. Funke G, Bernard KA. Coryneform gram-positive rods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: American Society for Microbiology, 2003:472-501.
18. Martínez-Martínez L, Suárez AI, Ortega MC, et al. Comparative in vitro activities of new quinolones against coryneform bacteria. Antimicrob Agents Chemother 1994; 38:1439-41.
19. Funke G, Pünter V, von Graevenitz A. Antimicrobial susceptibility patterns of some recently established coryneform bacteria. Antimicrob Agents Chemother 1996; 40:2874-8.
20. Funke G, Lawson PA, Nolte FS, et al. Aureobacterium resistens sp. nov. exhibiting vancomycin resistance and teicoplanin susceptibility. FEMS Microbiol Lett 1998; 158:89-93.
21. Jones EM, MacGowan AP. Antimicrobial chemotherapy of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Infect Dis 1995; 14:165-75.
22. Safdar A, Armstrong D. Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). J Clin Microbiol 2003; 41:483-5.
23. Andrews JM, Wise R. Susceptibility testing of Bacillus species. J Antimicrob Chemother 2002; 49:1039-46.
24. Weber DJ, Saviteer SM, Rutalla WA, et al. In vitro susceptibility of Bacillus spp. to selected antimicrobial agents. Antimicrob Agents Chemother 1988; 32:642-5.
25. Swenson JM, Facklam RR, Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother 1990; 34:543-9.
26. Husni RN, Gordon SM, Washington JA, et al. Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis 1997; 25:1048-55.
27. de la Maza L, Ruoff KL, Ferraro MJ. In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother 1989; 33:1383-4.
28. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003; 47:337-41.
29. Deye G, Lewis J, Patterson J, et al. A case of Leuconostoc ventriculitis with resistance to carbapenem antibiotics. Clin Infect Dis 2003; 37: 869-70.
30. Ruoff KL. Nutritionally variant streptococci. Clin Microbiol Rev 1991; 4:184-90.
31. Murray CK, Walter EA, Crawford S, et al. Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. Clin Infect Dis 2001; 32:e140-2.
32. Rossolini GM, Walsh T, Amicosante G. The Aeromonas metallo-β-lactamases: genetics, enzymology, and contribution to drug resistance. Microb Drug Resist 1996; 2:245-51.
33. Bakken JS, Sanders CC, Clark RB, et al. β-Lactam resistance in Aeromonas spp. caused by inducible β-lactamases active against penicillins, cephalosporins, and carbapenems. Antimicrob Agents Chemother 1988; 32:1314-9.
34. Stock I, Wiedemann B. β-Lactam-susceptibility patterns of Plesiomonas shigelloides strains: importance of inoculum and medium. Scand J Infect Dis 2001; 33:692-6.
35. Farmer III JJ, Janda JM, Birkhead K. Vibrio, In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH, eds. Manual of clinical microbiology. 8th ed. Washington, DC: American Society for Microbiology, 2003:706-18.
36. Das M, Badley AD, Cockerill FR, et al. Infective endocarditis caused by HACEK microorganisms. Ann Rev Med 1997; 48:25-33.
37. Kugler KC, Biedenbach DJ, Jones RN. Determination of the antimicrobial activity of 29 clinically important compounds tested against fastidious HACEK group organisms. Diagn Microbiol Infect Dis 1999; 34:73-6.
38. Lu PL, Hsueh P-R, Hung C-C. Infective endocarditis complicated with progressive heart failure due to β-lactamase-producing Cardiobacterium hominis. J Clin Microbiol 2000; 38:2015-7.
39. Goldstein EJC, Citron DM, Merriam CV, et al. In vitro activities of a new des-fluoroquinolone, BMS 284756, and seven other antimicrobial agents against 151 isolates of Eikenella corrodens. Antimicrob Agents Chemother 2002; 46:1141-3.
40. Sordillo EM, Rendel M, Sood R, et al. Septicemia due to β-lactamase-positive Kingella kingae. Clin Infect Dis 1993; 17:818-9.
41. Lion C, Lozniewski A, Rosner V, et al. Lung abscess due to β-lactamase-producing Pasteurella multocida. Clin Infect Dis 1999; 29:1345-6.
42. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species. Antimicrob Agents Chemother 2002; 46:3068-70.
43. Citron DM, Warren YA, Fernandez HT, et al. Broth microdilution and disk diffusion tests for susceptibility testing of Pasteurella species from human clinical specimens. J Clin Microbiol 2005; 43:2485-8.
44. Engberg J, Aarestrup FM, Taylor DE, et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7:24-34.
45. Murphy GS Jr, Echeverria P, Jackson LR, et al. Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler's diarrhea in US troops deployed to Thailand in 1994. Clin Infect Dis 1996; 22:868-9.
46. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982-2001. Emerg Infect Dis 2002; 8:1501-3.
47. Wallace RJ, Steingrube VA, Nash DR, et al. BRO β-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal β-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother 1989; 33:1845-54.
48. Doern GV, Tubert TA. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother 1988; 32:259-61.
49. Felmingham D, Gruneberg RN. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens, 1992-1993: the Alexander Project. The Alexander Project Group. J Antimicrob Chemother 1996; 38 (Suppl A):1-57.
50. Clinical and Laboratory Standards Institute. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Approved standard M45-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.